The natural history of treated Parkinson's disease in an incident, community based cohort

BackgroundOur understanding of the natural history of idiopathic Parkinson's disease (PD) remains limited. In the era of potential disease modifying therapies, there is an urgent need for studies assessing the natural evolution of treated PD from onset so that relevant outcome measures can be i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neurology, neurosurgery and psychiatry neurosurgery and psychiatry, 2011-10, Vol.82 (10), p.1112-1118
Hauptverfasser: Evans, Jonathan R, Mason, Sarah L, Williams-Gray, Caroline H, Foltynie, Thomas, Brayne, Carol, Robbins, Trevor W, Barker, Roger A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1118
container_issue 10
container_start_page 1112
container_title Journal of neurology, neurosurgery and psychiatry
container_volume 82
creator Evans, Jonathan R
Mason, Sarah L
Williams-Gray, Caroline H
Foltynie, Thomas
Brayne, Carol
Robbins, Trevor W
Barker, Roger A
description BackgroundOur understanding of the natural history of idiopathic Parkinson's disease (PD) remains limited. In the era of potential disease modifying therapies, there is an urgent need for studies assessing the natural evolution of treated PD from onset so that relevant outcome measures can be identified for clinical trials. No previous studies have charted progression in unselected patients followed from the point of diagnosis.MethodsA representative cohort of 132 PD patients was followed from diagnosis for up to 7.9 years (mean 5.2 years). Comprehensive clinical and neuropsychological evaluations were performed every 18 months. Disease progression was evaluated using well validated clinical measures (motor progression and development of dyskinesia on the Unified PD Rating Scale and Hoehn–Yahr scale, dementia onset according to DSM-IV criteria). Multi-level linear modelling was used to chart the nature and rate of progression in parkinsonian symptoms and signs over time. The prognostic importance of baseline demogr`aphic, clinical and genetic variables was evaluated using survival analysis.ResultsAxial (gait and postural) symptoms evolve more rapidly than other motor features of PD and appear to be the best index of disease progression. Conversely, conventional outcome measures are relatively insensitive to change over time. Earlier onset of postural instability (Hoehn–Yahr stage 3) is strongly associated with increased age at disease onset and has a significant impact on quality of life.ConclusionsDementia risk is associated with increased age, impaired baseline semantic fluency and the MAPT H1/H1 genotype. The efficacy of disease modifying therapies may be more meaningfully assessed in terms of their effects in delaying the major milestones of PD, such as postural instability and dementia, since it is these that have the greatest impact on patients.
doi_str_mv 10.1136/jnnp.2011.240366
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_907182219</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>907182219</sourcerecordid><originalsourceid>FETCH-LOGICAL-b607t-296bdb3554d6fc0c9186b8a124d14f8cf7c0fffc7460bda0ac53dd482c2b0f7b3</originalsourceid><addsrcrecordid>eNqNkdtrFDEUxoNY7Lb67pMERPpgZ81lJjPzqEvV0lIr1NtTyJWddSZZkwy4_70ZZu2CUDAPJ4TzO1_O-Q4AzzFaYkzZm41z2yVBGC9JiShjj8ACl6wpKEXfH4MFQoQUFFXoGJzEuEHTadon4JjgqqUVpgvw425toBNpDKKH6y4mH3bQW5iCEcloeCvCz85F784i1F00IhrYOShcjqrTxqVzqPwwjK5LOyhzWuf32of0FBxZ0UfzbH-fgi_vL-5WH4vrTx8uV2-vC8lQnQrSMqklrapSM6uQanHDZCMwKTUubaNsrZC1VtUlQ1ILJFRFtS4boohEtpb0FJzNutvgf40mJj50UZm-F874MfIW1bghBLeZfPkPufFjcLk5jusm_8gwoZlCM6WCjzEYy7ehG0TYcYz45DqfXOeT63x2PZe82AuPcjD6vuCvzRl4tQdEVKK3QWTz4oErK5qlJqFi5vIizO_7fN4BZzWtK37zdcU_t-SGXr37xm8z_3rm5bD5nzbPD_Rh9IfwP5IxtU0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1781246123</pqid></control><display><type>article</type><title>The natural history of treated Parkinson's disease in an incident, community based cohort</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><creator>Evans, Jonathan R ; Mason, Sarah L ; Williams-Gray, Caroline H ; Foltynie, Thomas ; Brayne, Carol ; Robbins, Trevor W ; Barker, Roger A</creator><creatorcontrib>Evans, Jonathan R ; Mason, Sarah L ; Williams-Gray, Caroline H ; Foltynie, Thomas ; Brayne, Carol ; Robbins, Trevor W ; Barker, Roger A</creatorcontrib><description>BackgroundOur understanding of the natural history of idiopathic Parkinson's disease (PD) remains limited. In the era of potential disease modifying therapies, there is an urgent need for studies assessing the natural evolution of treated PD from onset so that relevant outcome measures can be identified for clinical trials. No previous studies have charted progression in unselected patients followed from the point of diagnosis.MethodsA representative cohort of 132 PD patients was followed from diagnosis for up to 7.9 years (mean 5.2 years). Comprehensive clinical and neuropsychological evaluations were performed every 18 months. Disease progression was evaluated using well validated clinical measures (motor progression and development of dyskinesia on the Unified PD Rating Scale and Hoehn–Yahr scale, dementia onset according to DSM-IV criteria). Multi-level linear modelling was used to chart the nature and rate of progression in parkinsonian symptoms and signs over time. The prognostic importance of baseline demogr`aphic, clinical and genetic variables was evaluated using survival analysis.ResultsAxial (gait and postural) symptoms evolve more rapidly than other motor features of PD and appear to be the best index of disease progression. Conversely, conventional outcome measures are relatively insensitive to change over time. Earlier onset of postural instability (Hoehn–Yahr stage 3) is strongly associated with increased age at disease onset and has a significant impact on quality of life.ConclusionsDementia risk is associated with increased age, impaired baseline semantic fluency and the MAPT H1/H1 genotype. The efficacy of disease modifying therapies may be more meaningfully assessed in terms of their effects in delaying the major milestones of PD, such as postural instability and dementia, since it is these that have the greatest impact on patients.</description><identifier>ISSN: 0022-3050</identifier><identifier>EISSN: 1468-330X</identifier><identifier>DOI: 10.1136/jnnp.2011.240366</identifier><identifier>PMID: 21593513</identifier><identifier>CODEN: JNNPAU</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd</publisher><subject>Activities of daily living ; Age Factors ; Aged ; Antiparkinson Agents - therapeutic use ; Biological and medical sciences ; Clinical trials ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Dementia ; Dementia - diagnosis ; Dementia - drug therapy ; Disease Progression ; Female ; Genotype ; Haplotypes - genetics ; Humans ; Kaplan-Meier Estimate ; Levodopa - therapeutic use ; Male ; Medical sciences ; Mortality ; Neurologic Examination - drug effects ; Neurology ; Neuropsychological Tests ; Parkinson Disease - diagnosis ; Parkinson Disease - drug therapy ; Parkinson's disease ; Pathology ; Quality of Life ; Research paper ; Studies ; tau Proteins - genetics</subject><ispartof>Journal of neurology, neurosurgery and psychiatry, 2011-10, Vol.82 (10), p.1112-1118</ispartof><rights>2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><rights>2015 INIST-CNRS</rights><rights>2011 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b607t-296bdb3554d6fc0c9186b8a124d14f8cf7c0fffc7460bda0ac53dd482c2b0f7b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jnnp.bmj.com/content/82/10/1112.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttps://jnnp.bmj.com/content/82/10/1112.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,55321,77342,77373,77401,77427</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24532406$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21593513$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Evans, Jonathan R</creatorcontrib><creatorcontrib>Mason, Sarah L</creatorcontrib><creatorcontrib>Williams-Gray, Caroline H</creatorcontrib><creatorcontrib>Foltynie, Thomas</creatorcontrib><creatorcontrib>Brayne, Carol</creatorcontrib><creatorcontrib>Robbins, Trevor W</creatorcontrib><creatorcontrib>Barker, Roger A</creatorcontrib><title>The natural history of treated Parkinson's disease in an incident, community based cohort</title><title>Journal of neurology, neurosurgery and psychiatry</title><addtitle>J Neurol Neurosurg Psychiatry</addtitle><addtitle>J Neurol Neurosurg Psychiatry</addtitle><description>BackgroundOur understanding of the natural history of idiopathic Parkinson's disease (PD) remains limited. In the era of potential disease modifying therapies, there is an urgent need for studies assessing the natural evolution of treated PD from onset so that relevant outcome measures can be identified for clinical trials. No previous studies have charted progression in unselected patients followed from the point of diagnosis.MethodsA representative cohort of 132 PD patients was followed from diagnosis for up to 7.9 years (mean 5.2 years). Comprehensive clinical and neuropsychological evaluations were performed every 18 months. Disease progression was evaluated using well validated clinical measures (motor progression and development of dyskinesia on the Unified PD Rating Scale and Hoehn–Yahr scale, dementia onset according to DSM-IV criteria). Multi-level linear modelling was used to chart the nature and rate of progression in parkinsonian symptoms and signs over time. The prognostic importance of baseline demogr`aphic, clinical and genetic variables was evaluated using survival analysis.ResultsAxial (gait and postural) symptoms evolve more rapidly than other motor features of PD and appear to be the best index of disease progression. Conversely, conventional outcome measures are relatively insensitive to change over time. Earlier onset of postural instability (Hoehn–Yahr stage 3) is strongly associated with increased age at disease onset and has a significant impact on quality of life.ConclusionsDementia risk is associated with increased age, impaired baseline semantic fluency and the MAPT H1/H1 genotype. The efficacy of disease modifying therapies may be more meaningfully assessed in terms of their effects in delaying the major milestones of PD, such as postural instability and dementia, since it is these that have the greatest impact on patients.</description><subject>Activities of daily living</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Antiparkinson Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Clinical trials</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Dementia</subject><subject>Dementia - diagnosis</subject><subject>Dementia - drug therapy</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Genotype</subject><subject>Haplotypes - genetics</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Levodopa - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mortality</subject><subject>Neurologic Examination - drug effects</subject><subject>Neurology</subject><subject>Neuropsychological Tests</subject><subject>Parkinson Disease - diagnosis</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson's disease</subject><subject>Pathology</subject><subject>Quality of Life</subject><subject>Research paper</subject><subject>Studies</subject><subject>tau Proteins - genetics</subject><issn>0022-3050</issn><issn>1468-330X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkdtrFDEUxoNY7Lb67pMERPpgZ81lJjPzqEvV0lIr1NtTyJWddSZZkwy4_70ZZu2CUDAPJ4TzO1_O-Q4AzzFaYkzZm41z2yVBGC9JiShjj8ACl6wpKEXfH4MFQoQUFFXoGJzEuEHTadon4JjgqqUVpgvw425toBNpDKKH6y4mH3bQW5iCEcloeCvCz85F784i1F00IhrYOShcjqrTxqVzqPwwjK5LOyhzWuf32of0FBxZ0UfzbH-fgi_vL-5WH4vrTx8uV2-vC8lQnQrSMqklrapSM6uQanHDZCMwKTUubaNsrZC1VtUlQ1ILJFRFtS4boohEtpb0FJzNutvgf40mJj50UZm-F874MfIW1bghBLeZfPkPufFjcLk5jusm_8gwoZlCM6WCjzEYy7ehG0TYcYz45DqfXOeT63x2PZe82AuPcjD6vuCvzRl4tQdEVKK3QWTz4oErK5qlJqFi5vIizO_7fN4BZzWtK37zdcU_t-SGXr37xm8z_3rm5bD5nzbPD_Rh9IfwP5IxtU0</recordid><startdate>20111001</startdate><enddate>20111001</enddate><creator>Evans, Jonathan R</creator><creator>Mason, Sarah L</creator><creator>Williams-Gray, Caroline H</creator><creator>Foltynie, Thomas</creator><creator>Brayne, Carol</creator><creator>Robbins, Trevor W</creator><creator>Barker, Roger A</creator><general>BMJ Publishing Group Ltd</general><general>BMJ Publishing Group</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7TK</scope></search><sort><creationdate>20111001</creationdate><title>The natural history of treated Parkinson's disease in an incident, community based cohort</title><author>Evans, Jonathan R ; Mason, Sarah L ; Williams-Gray, Caroline H ; Foltynie, Thomas ; Brayne, Carol ; Robbins, Trevor W ; Barker, Roger A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b607t-296bdb3554d6fc0c9186b8a124d14f8cf7c0fffc7460bda0ac53dd482c2b0f7b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Activities of daily living</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Antiparkinson Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Clinical trials</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Dementia</topic><topic>Dementia - diagnosis</topic><topic>Dementia - drug therapy</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Genotype</topic><topic>Haplotypes - genetics</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Levodopa - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mortality</topic><topic>Neurologic Examination - drug effects</topic><topic>Neurology</topic><topic>Neuropsychological Tests</topic><topic>Parkinson Disease - diagnosis</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson's disease</topic><topic>Pathology</topic><topic>Quality of Life</topic><topic>Research paper</topic><topic>Studies</topic><topic>tau Proteins - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Evans, Jonathan R</creatorcontrib><creatorcontrib>Mason, Sarah L</creatorcontrib><creatorcontrib>Williams-Gray, Caroline H</creatorcontrib><creatorcontrib>Foltynie, Thomas</creatorcontrib><creatorcontrib>Brayne, Carol</creatorcontrib><creatorcontrib>Robbins, Trevor W</creatorcontrib><creatorcontrib>Barker, Roger A</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing &amp; Allied Health Database</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Science Journals (ProQuest Database)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>Neurosciences Abstracts</collection><jtitle>Journal of neurology, neurosurgery and psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Evans, Jonathan R</au><au>Mason, Sarah L</au><au>Williams-Gray, Caroline H</au><au>Foltynie, Thomas</au><au>Brayne, Carol</au><au>Robbins, Trevor W</au><au>Barker, Roger A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The natural history of treated Parkinson's disease in an incident, community based cohort</atitle><jtitle>Journal of neurology, neurosurgery and psychiatry</jtitle><stitle>J Neurol Neurosurg Psychiatry</stitle><addtitle>J Neurol Neurosurg Psychiatry</addtitle><date>2011-10-01</date><risdate>2011</risdate><volume>82</volume><issue>10</issue><spage>1112</spage><epage>1118</epage><pages>1112-1118</pages><issn>0022-3050</issn><eissn>1468-330X</eissn><coden>JNNPAU</coden><abstract>BackgroundOur understanding of the natural history of idiopathic Parkinson's disease (PD) remains limited. In the era of potential disease modifying therapies, there is an urgent need for studies assessing the natural evolution of treated PD from onset so that relevant outcome measures can be identified for clinical trials. No previous studies have charted progression in unselected patients followed from the point of diagnosis.MethodsA representative cohort of 132 PD patients was followed from diagnosis for up to 7.9 years (mean 5.2 years). Comprehensive clinical and neuropsychological evaluations were performed every 18 months. Disease progression was evaluated using well validated clinical measures (motor progression and development of dyskinesia on the Unified PD Rating Scale and Hoehn–Yahr scale, dementia onset according to DSM-IV criteria). Multi-level linear modelling was used to chart the nature and rate of progression in parkinsonian symptoms and signs over time. The prognostic importance of baseline demogr`aphic, clinical and genetic variables was evaluated using survival analysis.ResultsAxial (gait and postural) symptoms evolve more rapidly than other motor features of PD and appear to be the best index of disease progression. Conversely, conventional outcome measures are relatively insensitive to change over time. Earlier onset of postural instability (Hoehn–Yahr stage 3) is strongly associated with increased age at disease onset and has a significant impact on quality of life.ConclusionsDementia risk is associated with increased age, impaired baseline semantic fluency and the MAPT H1/H1 genotype. The efficacy of disease modifying therapies may be more meaningfully assessed in terms of their effects in delaying the major milestones of PD, such as postural instability and dementia, since it is these that have the greatest impact on patients.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd</pub><pmid>21593513</pmid><doi>10.1136/jnnp.2011.240366</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-3050
ispartof Journal of neurology, neurosurgery and psychiatry, 2011-10, Vol.82 (10), p.1112-1118
issn 0022-3050
1468-330X
language eng
recordid cdi_proquest_miscellaneous_907182219
source MEDLINE; BMJ Journals - NESLi2
subjects Activities of daily living
Age Factors
Aged
Antiparkinson Agents - therapeutic use
Biological and medical sciences
Clinical trials
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Dementia
Dementia - diagnosis
Dementia - drug therapy
Disease Progression
Female
Genotype
Haplotypes - genetics
Humans
Kaplan-Meier Estimate
Levodopa - therapeutic use
Male
Medical sciences
Mortality
Neurologic Examination - drug effects
Neurology
Neuropsychological Tests
Parkinson Disease - diagnosis
Parkinson Disease - drug therapy
Parkinson's disease
Pathology
Quality of Life
Research paper
Studies
tau Proteins - genetics
title The natural history of treated Parkinson's disease in an incident, community based cohort
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T18%3A21%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20natural%20history%20of%20treated%20Parkinson's%20disease%20in%20an%20incident,%20community%20based%20cohort&rft.jtitle=Journal%20of%20neurology,%20neurosurgery%20and%20psychiatry&rft.au=Evans,%20Jonathan%20R&rft.date=2011-10-01&rft.volume=82&rft.issue=10&rft.spage=1112&rft.epage=1118&rft.pages=1112-1118&rft.issn=0022-3050&rft.eissn=1468-330X&rft.coden=JNNPAU&rft_id=info:doi/10.1136/jnnp.2011.240366&rft_dat=%3Cproquest_cross%3E907182219%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1781246123&rft_id=info:pmid/21593513&rfr_iscdi=true